The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Anticancer drug resistance: An update and perspective
Open accessAbstract
inhibitors are variable and fall into three categories, (i) new point mutations in KRas, or multiple copies of KRAS G12C which lead to higher expression level of the mutant protein; (ii) mutations in genes other than KRAS; (iii) original cancer transitioning to other cancer(s). Resistance to adagrasib, an experimental antitumor agent exerting its cytotoxic effect as a covalent inhibitor of the G12C KRas, indicated that half of the cases present multiple KRas mutations as well as allele amplification. Redundant or parallel pathways included MET amplification; emerging driver mutations in NRAS, BRAF, MAP2K1, and RET; gene fusion events in ALK, RET, BRAF, RAF1, and FGFR3; and loss-of-function mutations in NF1 and PTEN tumor suppressors. In the current review we discuss the molecular mechanisms underlying drug resistance while focusing on those emerging to common targeted cancer drivers. We also address questions of why cancers with a common driver mutation are unlikely to evolve a common drug resistance mechanism, and whether one can predict the likely mechanisms that the tumor cell may develop. These vastly important and tantalizing questions in drug discovery, and broadly in precision medicine, are the focus of our present review. We end with our perspective, which calls for target combinations to be selected and prioritized with the help of the emerging massive compute power which enables artificial intelligence, and the increased gathering of data to overcome its insatiable needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–212 of 212
Adariani, S. R., Jasemi, N. S. K., Bazgir, F., Wittich, C., Amin, E., Seidel, C. A. M., Dvorský, R., & Ahmadian, M. R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100626 · Cited by 23
Targeted drug combination therapy design based on driver genes
Zsákai, L., Sipos, A., Dobos, J., Erös, D., Szántai-Kis, C., Bánhegyi, P., Pató, J., Őrfi, L., Matula, Z., Mikala, G., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26985 · Cited by 22
FPGA based neural network accelerators
Kim, J.-Y. (2020) · Advances in computers · doi:10.1016/bs.adcom.2020.11.002 · Cited by 22
Metabolic Mechanisms of Drug Resistance in Leukemia
Knoechel, B., & Aster, J. C. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.10.005 · Cited by 21
Haupt, S., Zeilmann, A., Ahadova, A., Bläker, H., Doeberitz, M. V. K., Kloor, M., & Heuveline, V. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008970 · Cited by 20
Splice variants of RAS—translational significance
Rásó, E. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09920-8 · Cited by 19
Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients
Yang, I. S., & Kim, S. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2011-y · Cited by 17
Driver mutations in oncogenesis
Morjaria, S. (2020) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_26_2020 · Cited by 15
Drugging multiple same-allele driver mutations in cancer
Nussinov, R., Zhang, M., Maloney, R., & Jang, H. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1905628 · Cited by 14
Self-citationSun, T., Zhao, Q., Zhang, C., Cao, L., Song, M., Maimela, N. R., Liu, S., Wang, J., Gao, Q., Qin, G., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2190 · Cited by 10
Induction of a Timed Metabolic Collapse to Overcome Cancer ChemoresistancePreprint
van Gastel, N., Spinelli, J. B., Sharda, A., Schajnovitz, A., Baryawno, N., Rhee, C., Oki, T., Grace, E., Soled, H. J., Vidoudez, C., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3537802 · Cited by 7
Isoform-specific Ras expression and signalling.
Newlaczyl, A. U. (2016) · University of Liverpool · doi:10.17638/03000021 · Cited by 1
Cited by
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Self-citationLiu, Y., Zhang, W., Jang, H., & Nussinov, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02022 · Cited by 10
Self-citation
Metadata
- Authors
- Nussinov, R., Tsai, C.-J., & Jang, H.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 59
- Pages
- 100796
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W4200191138
- Cited by
- 386
- References
- 212
- FWCI
- 32.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.